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Abstract
Background—Patients with acute pulmonary embolism (PE) exhibit wide variation in clinical 
presentation and outcomes. Our understanding of the pathophysiologic mechanisms differentiating 
low-risk and high-risk PE is limited, so current risk-stratification efforts often fail to predict 
clinical deterioration and are insufficient to guide management.
Objectives—To improve our understanding of the physiology differentiating low-risk from high-
risk PE, we conducted the first-ever high-throughput metabolomics analysis (843 named 
metabolites) comparing PE patients across risk strata within a nested case-control study.
Patients/Methods—We enrolled 92 patients diagnosed with acute PE and collected plasma 
within 24 hours of PE diagnosis. We used linear regression and pathway analysis to identify 
metabolites and pathways associated with PE risk-strata.
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Results—When we compared 46 low-risk to 46 intermediate/high-risk PE, 50 metabolites were 
significantly different after multiple testing correction. These metabolites were enriched in the 
following pathways: TCA Cycle, Fatty Acid Metabolism (Acyl Carnitine), and Purine 
Metabolism, (Hypo)Xanthine/Inosine Containing. Additionally, Energy, Nucleotide, and Amino 
Acid pathways were down-regulated in intermediate/high-risk PE patients. When we compared 28 
intermediate-risk to 18 high-risk PE patients, 41 metabolites differed at a nominal p-value level. 
These metabolites were enriched in Fatty Acid Metabolism (Acyl Cholines), and Hemoglobin and 
Porphyrin Metabolism.
Conclusion—Our results suggest that high-throughput metabolomics can provide insight into 
the pathophysiology of PE. Specifically, changes in circulating metabolites reflect compromised 
energy metabolism in intermediate/high-risk PE patients. These findings demonstrate the 
important role metabolites play in the pathophysiology of PE and highlight metabolomics as a 
potential tool for risk stratification of PE.
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Introduction
Patients with acute pulmonary embolism (PE) exhibit wide variation in both clinical 
presentation and outcomes. Mortality ranges from <1% for low-risk PE patients to >50% for 
high-risk/massive PE patients who present with cardiovascular collapse or shock [1]. For 
intermediate-risk/submassive patients who present with large PE and evidence of right 
ventricular (RV) dysfunction, but are hemodynamically stable, mortality is estimated at 
7.7%–15% [1, 2].
Currently, clinicians risk-stratify patients using a combination of imaging tests (e.g. 
echocardiography, computed tomography pulmonary angiography [CTPA]) and biomarkers 
(e.g. troponin and brain natriuretic peptides) to identify RV dysfunction. However, measures 
of RV dysfunction often fail to predict clinical deterioration and are insufficient to guide 
management in many cases. Other intuitive measures, such as clot burden, are also 
inadequate predictors of adverse outcomes after PE [2–4]. Our ability to risk-stratify patients 
is limited by our understanding of the pathophysiology of clinical deterioration after PE; 
including the metabolic changes associated with acute thromboembolism. A better 
understanding of the physiology that differentiates low-risk from high-risk PE is needed to 
improve our ability to risk-stratify patients.
Using modern, high-throughput metabolomics, we can now assess a broad array of 
metabolites and metabolic profiles associated with disease risk and changes in physiologic 
status. However, metabolomics technology has not yet been used to compare patients across 
PE risk-strata. We performed the first high-throughput metabolomics study comparing PE 
patients across different risk-strata (low-, intermediate- and high-risk), with the goal of 
identifying specific metabolites and pathways that are associated with these clinically 
relevant PE subtypes.
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Materials/Methods
Study population
We performed a case-control study nested within a prospective non-interventional cohort 
study of consecutive adult patients (age ≥18 years) who presented to the Emergency 
Department of Massachusetts General Hospital and diagnosed with PE between October 
2008 and December 2011. Details of enrollment have been described previously [5]. For the 
current analysis, all enrolled patients had radiographically diagnosed PE, defined as a filling 
defect in a pulmonary artery on CTPA. Patients were eligible if PE was diagnosed within 24 
hours of Emergency Department registration. Patients were excluded if they were <18 years 
old, did not provide informed consent or were not available for follow up (e.g. homeless, 
prisoners).
Study staff used a standard data collection form to abstract the following information from 
medical records: demographic data, comorbid illnesses, vital signs, laboratory results, 
radiological findings and treatments. The study was approved by the Human Research 
Committee of Partners HealthCare (protocol 2008-P-002001). All patients provided written 
informed consent prior to blood sample collection.
Blood samples were obtained from enrolled patients within 24 hours of PE diagnosis (based 
on the time CTPA was performed). Samples were collected in potassium EDTA tubes, 
centrifuged, transferred to 500µL vials and stored in a −70°C freezer. Samples were kept 
frozen until they were shipped for metabolomic analysis on dry ice. For the current analysis, 
we only included patients with a blood sample that had been processed and frozen within 60 
minutes of collection.
To gather data used to classify study patients as to whether they had low/intermediate/high-
risk PE, study staff reviewed medical records and interviewed patients and their clinicians 
every day for five days after enrollment. We also performed follow up using a validated 
combination of telephone calls and computer medical record review on days five and 30 to 
identify deaths, recurrent PE or bleeding events after hospital discharge [6].
Forty-six intermediate/high-risk PE patients met the study criteria and had blood samples 
available that were processed within 60 minutes of blood draw. These patients were 1:1 
matched to 46 low-risk patients on age, gender, and cancer status (any vs. no history of 
malignancy). Intermediate/high-risk PE were defined as PE in a lobar or main pulmonary 
artery with: 1) hemodynamic instability (hypotension, pulselessness, persistent profound 
bradycardia, or need for advanced cardiac life support); 2) evidence of RV dysfunction (RV 
dilatation, hypokinesis or septal bowing on echocardiogram); 3) elevated N-terminal pro-
brain natriuretic peptide (NT-proBNP) >500 pg/ml; or 4) myocardial necrosis (troponin t 
>0.1 ng/ml). Low-risk PE was defined as segmental or smaller PE without markers of 
adverse prognosis used to define intermediate/high-risk PE. Intermediate/high-risk PE was 
then divided into intermediate- and high-risk, with high-risk PE defined as PE with 
persistent hypotension or need for vasopressor therapy, need for advanced cardiac life 
support, occurrence of an unstable cardiac dysrhythmia, need for thrombolysis or 
thrombectomy, need for positive pressure ventilation, or death. Among the 46 intermediate- 
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and high-risk patients, 18 (39%) had high-risk PE and 28 (61%) had intermediate-risk PE. 
Demographics of the analyzed patients are shown in Table 1.
Metabolomics assays
Metabolomics assays were conducted at Metabolon (Morrisville, NC, USA) using tandem 
ultra-performance liquid chromatography followed by mass spectrometry (UPLC/MS). 
UPLC/MS was done using an ACQUITY ultra-performance liquid chromatography (UPLC) 
(Waters Corporation, MA, USA) coupled to an Q-Exactive high resolution/accurate mass 
spectrometer (Thermo Scientific Corporation, MA, USA) interfaced with heated 
electrospray ionization [7] and Orbitrap mass analyzer operated at 35,000 mass resolution. 
These metabolomics assays have been previously described in detail [8]. Briefly, after 
sample accession and preparation, each sample was divided into one backup aliquot and four 
aliquots for the different measurement methods: 1) acidic positive ion conditions optimized 
for more hydrophilic compounds, 2) acidic positive ion conditions optimized for more 
hydrophobic compounds, 3) basic negative ion optimized conditions using a separate 
dedicated C18 column, and 4) negative ionization following elution from a HILIC column. 
Compounds were identified by comparison to library entries of purified standards or 
recurrent unknown entities. Peaks were quantified using area-under-the-curve. Several 
normalization steps were performed including normalization to account for inter-day tuning 
differences and for volume available/utilized for extraction.
Statistical Analyses
We used multivariable linear regression to identify metabolites that differed between low-
risk and intermediate/high-risk PE as well as between intermediate- and high-risk PE. 
Metabolites were first transformed using the natural logarithm and then scaled to mean = 0 
and standard deviation = 1. Each metabolite was modeled as a continuous variable and 
regressed on risk status (low-risk vs. intermediate/high-risk PE or intermediate- vs. high-
risk) adjusting for age, sex, and cancer status. The False Discovery Rate (FDR) procedure by 
Benjamini and Hochberg [9] was used to account for multiple comparisons. FDR controls 
the proportion of false discoveries, i.e. the proportion of falsely rejected null hypotheses. 
Additionally, FDR adjustments represent a preferred alternative to the stringent Bonferroni 
correction [10] by balancing the power of our study against the ability to avoid false 
positives. We also used the non-parametric Wilcoxon two-sample test (also known as Mann-
Whitney U-Test) to assess the influence of non-normally distributed metabolites in the linear 
regression analysis.
To further identify specific pathways that were enriched (or depleted) in low-risk PE patients 
compared with intermediate/high-risk PE patients, we applied Fisher’s Exact test to the 
metabolites that were associated with PE risk subtypes at FDR-corrected p-value ≤0.05 in 
the linear regression analysis. Because there were no metabolites that differed between 
intermediate- and high-risk PE at an FDR-corrected p-value ≤0.05 (possibly due to low 
statistical power), we instead included all metabolites that showed association at a nominal 
p-value ≤0.05. To adjust for multiple testing in the pathway analysis, we used an FDR-
corrected p-value ≤0.2 to declare significance.
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In a post-hoc analysis we used linear regression to calculate how strong the metabolites 
identified as different (after multiple testing correction) between low-risk PE and 
intermediate/high-risk PE groups are associated with each of the individual components 
used to define low-risk and intermediate/high risk PE groups: myocardial necrosis, heart 
failure, hemodynamic instability and right ventricle (RV) dysfunction. In each individual 
analysis, intermediate/high-risk was defined as evidence of: myocardial necrosis (troponin 
levels ≥0.1 ng/ml, 8 participants identified), heart failure (NT-proBNP levels ≥500 pg/ml, 36 
participants identified), hemodynamic instability (SBP levels ≤ 90 mm Hg, 18 participants 
identified), RV dysfunction (RV dilatation or RV hypokinesis or RV bowing septum, 33 
participants identified). We acknowledge the low number of cases for myocardial necrosis 
and hemodynamic instability but we include the corresponding FDR-corrected p-values and 
think that showing all results creates a more detailed picture of the associations with the 
individual PE components.
Results
Metabolomics assays of serum samples from 92 patients (see Table 1 for demographics) 
using four methods resulted in 843 named metabolites measured: 367 with LC/MS negative, 
77 with LC/MS Polar, 205 with LC/MS Positive Early, and 207 with LC/MS Positive Late. 
The metabolites were structured in eight super-pathways (Amino Acid, Carbohydrate, 
Cofactors and Vitamins, Energy, Lipid, Nucleotide, Peptide and Xenobiotics) and 91 sub-
pathways such as tricarboxylic acid (TCA) cycle, Fatty Acid Metabolism and Sphingolipid 
Metabolism. The assignment of each metabolite to super- and sub-pathways is shown in the 
supplementary data.
Low-risk PE vs. intermediate/high-risk PE
We identified 158 metabolites that differed between low-risk PE and intermediate/high-risk 
PE at a nominal p-value level of 0.05 (Figure 1, A and B). After multiple testing correction, 
50 metabolites were significant at FDR-corrected p-value ≤0.05 (Figure 1, C and D). A heat 
map of these metabolites and a heat map of the correlations between them are shown in 
Figure S1 and Figure S2, respectively. Results for all metabolites, including calculated p-
values and FDR-corrected p-values, can be found in supplementary Table S1. The top three 
(p-value ≤9×10−5, FDR-corrected p-value ≤0.017) identified metabolites were: xanthosine, 
alpha-ketoglutarate, and arachidoylcarnitine (C20). Similar results were found with the 
Wilcoxon two sample test (data not shown).
Pathway analysis identified three sub-pathways (TCA Cycle, Fatty Acid Metabolism (Acyl 
Carnitine), and Purine Metabolism, (Hypo)Xanthine/Inosine Containing) and three super-
pathways (Energy, Nucleotide, and Amino Acid) as significantly enriched (FDR-corrected 
p-value ≤0.2) in the 50 metabolites that were significantly different (FDR-corrected p-value 
≤0.05) between low-risk and intermediate/high-risk PE patients (Table 2). The complete 
results of the pathway analysis are shown in supplementary Table S2.
The most significant enrichment (FDR-corrected p-value = 0.002) was found for TCA 
Cycle, and Fatty Acid Metabolism (Acyl Carnitine) pathways. Five of the nine metabolites 
in the TCA Cycle pathway and nine of the 31 metabolites in the Fatty Acid Metabolism 
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(Acyl Carnitine) pathway were depleted in the intermediate/high-risk group compared to the 
low-risk group. Interestingly, when considering all measured metabolites belonging to the 
TCA Cycle pathway, all but one of them had higher values in the intermediate/high-risk PE 
group compared with the low-risk PE group. The five significantly different metabolites 
driving the enrichment of the TCA Cycle pathway were: alpha-ketoglutarate, malate, 
isocitrate, fumarate and cis-aconitate. Enrichment of the Fatty Acid Metabolism (Acyl 
Carnitine) pathway was driven by: arachidoylcarnitine (C20), stearoylcarnitine (C18), 
linoleoylcarnitine (C18:2), 3-hydroxybutyrylcarnitine (2 isomers), myristoylcarnitine (C14), 
linolenoylcarnitine (C18:3), suberoylcarnitine (C8-DC) and oleoylcarnitine (C18:1).
Purine Metabolism, (Hypo)Xanthine/Inosine Containing is the third pathway that was 
enriched in the metabolites associated with intermediate/high-risk PE patients. This pathway 
was driven by xanthosine and hypoxanthine (FDR-corrected p-value ≤0.05), which were 
both higher in the intermediate/high risk PE groups compared with the low-risk PE group.
Pearson correlations among all measured acyl carnitines are shown in supplementary Figure 
S3. All acyl carnitines were positively correlated to each other.
Metabolites identified as different between low-risk and intermediate/high-risk PE groups 
were also associated with the individual PE components heart failure and RV dysfunction. 
Most metabolites had similar effects and similar significance levels (Figure S4). These 
associations were different when analyzing the individual PE components hemodynamic 
instability and myocardial necrosis. We want to remind the reader the small sample sizes in 
the case of these two analyses: 8 cases of myocardial necrosis and 18 cases of hemodynamic 
instability.
Intermediate-risk PE vs. high-risk PE
We identified 41 metabolites that differed between intermediate-risk PE and high-risk PE at 
a nominal p-value level of 0.05 (Figure 2, A and B). After multiple testing correction, none 
of the metabolites were significant at an FDR-corrected p-value ≤0.05 (Figure 2, C and D). 
All tested metabolites, including calculated p-values and FDR-corrected p-values, are 
presented in supplementary Table S3. The top three (nominal p-value ≤0.008) identified 
metabolites were all assigned to the super-pathway Lipid: 1-palmitoyl-2-arachidonoyl-GPC 
(16:0/20:4n6), 1-stearoyl-GPI (18:0) and arachidonoylcholine. Similar results were observed 
with the Wilcoxon two sample test (data not shown).
Two sub-pathways (Fatty Acid Metabolism (Acyl Choline), and Hemoglobin and Porphyrin 
Metabolism) were identified as enriched (FDR-corrected p-value ≤ 0.2, Table 3), among the 
41 metabolites that were nominally significantly different (p-value ≤0.05) between 
intermediate- and high-risk PE patients. The complete results of the enrichment analysis are 
shown in supplementary Table S4.
Fatty Acid Metabolism (Acyl Choline) showed the highest enrichment (FDR-corrected p-
value = 0.00043) with five out of seven metabolites in the pathway having higher levels in 
the high-risk PE group compared with the intermediate-risk PE group: arachidonoylcholine, 
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oleoylcholine, palmitoylcholine, docosahexaenoylcholine and dihomo-linolenoyl-choline. 
The remaining two metabolites showed the same trend at p-value ≤0.1.
The enrichment of Hemoglobin and Porphyrin Metabolism (FDR-corrected p-value =0.16) 
was driven by three of the seven metabolites in the pathway: I-urobilinogen, bilirubin (E,E) 
and bilirubin (Z,Z). Interestingly, all seven metabolites belonging to this pathway showed 
lower levels in the high-risk PE group compared with the intermediate-risk PE group.
Discussion
We performed the first high-throughput metabolomics study to examine differences 
associated with various strata of PE severity. We identified individual metabolites and 
pathways that differed significantly between low-risk and intermediate/high-risk PE as well 
as between intermediate- and high-risk PE. These findings highlight the important role 
metabolites play in the pathophysiology of PE and the role metabolomics may play in 
helping to further define the pathophysiology of PE and in risk-stratifying PE patients.
The super-pathways Energy, Nucleotide, and Amino Acid were enriched in metabolites that 
differed between low-risk and intermediate/high-risk PE patients. All metabolites driving 
this enrichment showed higher values in the intermediate/high-risk PE group, suggesting an 
up-regulation of these pathways in these patients. It is possible that high-risk PE decreases 
circulation sufficiently to compromise energy metabolism. This is consistent with previous 
studies that showed that anaerobic metabolism, measured by serum lactate is associated with 
adverse outcomes after PE [11, 12]. The role of the Nucleotide and Amino Acid super-
pathways in PE has not been previously described and should be studied further.
Acyl carnitines were identified as significantly different between low-risk and intermediate/
high-risk PE patients, while acyl cholines were different between intermediate and high-risk 
PE patients. Among the 50 metabolites identified as significantly different between low-risk 
and intermediate/high-risk PE, nine were acyl carnitines. These metabolites drove the 
observed enrichment of Fatty Acid Metabolism. These findings are consistent with a 
published study of venous thromboembolism (VTE) metabolomics, which reported that acyl 
carnitines levels were reduced in VTE cases compared with controls [13]. The authors note 
that patients with low levels of acyl carnitines C12:2 and C18:2 had an increased risk of 
incident VTE. We also observed an association with acyl carnitines C18:2 (FDR-corrected 
p-value = 0.03) and C12:0 (FDR-corrected p-value = 0.2), where the intermediate/high-risk 
PE groups had higher levels compared with the low-risk group. We compared subjects with 
low-risk PE to those with intermediate/high-risk PE, while Deguchi et al. compared subjects 
with and without VTE. Thus, acyl carnitines may be associated with both risk of incident 
VTE and PE severity. The exact role of these metabolites in VTE pathophysiology warrants 
further exploration.
We also found that short and medium chain acyl carnitines (≤ 20 carbon atoms), which were 
identified as different between low-risk PE and intermediate/high-risk PE, are highly 
correlated with each other and less correlated with long chain acyl carnitines (>20 carbon 
atoms), which were not significantly different between low-risk and intermediate/high-risk 
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PE (supplementary Figure S1). This suggests that short and medium chain (but not long 
chain) acyl carnitines are tightly regulated and play a role in PE severity.
When we compared intermediate with high-risk PE patients, we found that 5 acyl cholines 
differed between the two groups, driving the enrichment of Fatty Acid Metabolism (Acyl 
Cholines). Interestingly, acyl cholines had higher in high-risk PE patients than in 
intermediate-risk PE patients. The literature is very sparse on acyl cholines. Nevertheless, 
experiments on the embryos and larvae of sea urchins, sensitive to cholinergic compounds, 
showed that synthetically created arachidonoylcholine exhibited cholinomimetic activity 
similar to that of nicotine [14]. Smoking is an established risk factor for VTE, but whether 
this is related to the association between acyl cholines and PE severity in our study remains 
to be determined [15, 16].
Additionally, we observed the Hemoglobin and Porphyrin Metabolism pathway to be 
enriched when comparing high-risk PE group with the intermediate-risk PE group. This is 
interesting, and consistent with proteomics studies that observed lower levels of haptoglobin 
in high-risk PE subjects compared to less severe PE, including a study by Insenser and 
colleagues, who observed lower circulating haptoglobin concentrations in high-risk PE 
patients compared to less severe PE patients [17]. This finding was also seen in animal 
studies, using lung and serum samples from rats [18–20]. Lower levels of haptoglobin have 
also been observed in PE patients with severe pulmonary hypertension [21]. Haptoglobin has 
the capacity to bind to hemoglobin during hemolysis, which may affect vasoactive mediators 
and inflammatory processes [22, 23]. Our results, together with the existing literature, 
suggest hemoglobin metabolism down-regulation together with the down-regulation of 
haptoglobin may play an important role in the physiology of severe PE and may help 
identify patients at risk for adverse outcomes.
Our study has several strengths and some limitations. All of our subjects had 
radiographically confirmed PE, and blood samples drawn within 24 hours of PE diagnosis. 
Samples were all processed within 60 minutes of collection, minimizing the risk of pre-
processing effects. Moreover, our study was nested within a prospective cohort with highly 
granular outcome assessment. The risk of ascertainment or recall bias is therefore minimal. 
One limitation of our analysis is the number (n = 92) of study participants. Thus, results 
need to be interpreted with caution, in particular for the intermediate- to high-risk PE 
comparison (n = 46) where we used nominal p-values to assign statistical significance of 
individual metabolites. Another limitation of our study is that the metabolites were 
quantified as peak areas and not concentrations. In order to use metabolites in a clinical 
setting, new metabolomics assays need to be designed to measure their concentrations. 
However, our approach represents the state of the art in high-throughput metabolomics 
experiments. Additionally, due to the unique nature of our study (blood draw at the time of 
diagnosis and processing within one hour) it was not possible to replicate these findings in 
another population. Although the results of our study are consistent with the currently only 
other VTE metabolomics study [13], replication of our results in another study is desired. 
However, to the best of our knowledge, this is the largest study to date of VTE 
metabolomics, and the first study relating metabolomics to PE severity. Our results are 
statistically significant for the low-risk to intermediate/high-risk PE comparison, suggestive 
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in case of the intermediate to high-risk PE, and the fact that our findings are consistent with 
previous research supports the veracity of our results.
We performed the first study to examine metabolites and metabolic pathways in patients of 
varying PE severity. We identified individual metabolites as well as sub- and super-pathways 
that were significantly different between low-risk and intermediate/high-risk PE as well as 
between intermediate-risk and high-risk PE. These findings suggest that metabolites play an 
important role in the pathophysiology of PE. Larger studies are needed to confirm our 
results and to assess the potential use of metabolites as biomarkers for PE severity.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Essentials
• Risk-stratification often fails to predict clinical deterioration in pulmonary 
embolism (PE).
• First-ever high-throughput metabolomics analysis of risk-stratified PE 
patients.
• Changes in circulating metabolites reflect a compromised energy metabolism 
in PE.
• Metabolites play a key role in the pathophysiology and risk stratification of 
PE.
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Figure 1. 
Results of the linear regression analysis comparing intermediate/high-risk PE to low-risk PE. 
Each metabolite was regressed on the PE severity subtype (intermediate/high vs. low) 
adjusting for age, gender and cancer diagnosis. A Histogram of the p-values of the low-risk 
vs. intermediate/high-risk association analysis for 843 metabolites. B Table view of the 
distribution of p-values and their cumulative sum. C Histogram of the FDR-corrected p-
values of the low-risk vs. intermediate/high-risk association analysis for 843 metabolites. D 
Table view of the distribution of FDR-corrected p-values and their cumulative sum.
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Figure 2. 
Results of the linear regression analysis comparing high-risk to intermediate-risk PE. Each 
metabolite was regressed on the PE severity subtype (high-risk vs. intermediate-risk) 
adjusting for age, gender and cancer diagnosis. A Histogram of the p-values of the high-risk 
vs. intermediate-risk association analysis for 843 metabolites. B Table view of the 
distribution of p-values and their cumulative sum. C Histogram of the FDR-corrected p-
values of the high-risk vs. intermediate-risk association analysis for 843 metabolites. D 
Table view of the distribution of FDR-corrected p-values and their cumulative sum.
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Table 2
Pathways enrichment (FDR-corrected p-values ≤0.2) in the group of metabolites that differ significantly 
between intermediate/high-risk PE and low-risk PE. A complete list of the analysed metabolites is available in 
supplementary Table S1. The complete results of the pathway analysis is available in supplementary Table S3.
NMiP* NSDMiP† P-value FDR-corrected p-value
Super - Pathways
Energy 10 5 0.00012 0.00097
Nucleotide 34 6 0.01202 0.03204
Amino Acid 168 15 0.07002 0.14005
Sub - Pathways
TCA Cycle 9 5 0.00006 0.00289
Fatty Acid Metabolism (Acyl Carnitine) 31 9 0.00003 0.00289
Purine Metabolism, (Hypo)Xanthine/Inosine containing 7 3 0.00581 0.17629
Table 2 Notes:
*NMiP = Number of metabolites in pathway
†NSDMiP = Number of significantly different metabolites in pathway
J Thromb Haemost. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Zeleznik et al. Page 17
Table 3
Pathways enrichment (FDR-corrected p-values ≤0.2) in the group of metabolites that differ on a nominal scale 
between intermediate-risk and high-risk PE. A complete list of the analyzed metabolites is available in 
supplementary Table S2. The complete results of the pathway analysis is available in supplementary Table S4.
NMiP* NSDMiP† P-values FDR-corrected p-values
Sub – Pathways
Fatty Acid Metabolism (Acyl Choline) 7 5 4.7×10−6 0.00043
Hemoglobin and Porphyrin Metabolism 7 3 0.00351 0.15952
Table 3 Notes:
*NMiP = Number of metabolites in pathway
†NSDMiP = Number of significantly different metabolites in pathway
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